Citius Oncology Retains Jeffries to Consider Strategic Alternatives

MT Newswires Live01-06

Citius Pharmaceuticals' (CTXR) majority-owned subsidiary Citius Oncology (CTOR) said it has retained Jefferies as a financial advisor to evaluate possible strategic alternatives.

The company said alternatives being considered include partnerships, joint ventures, mergers, acquisitions, or licensing but has no specific timeline for a decision.

Citius Oncology Chief Executive Leonard Mazur said the "goal is to deliver value to shareholders."

Citius Oncology's main product Lymphir was recently approved by the US Food and Drug Administration for the treatment of relapsed or refractory Stage I-III cutaneous T-cell lymphoma following at least one prior systemic therapy.

Citius Oncology shares were up more than 6% and Citius Pharmaceuticals more than 5% in Monday's premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2501234862?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-06 21:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501234862","market":"fut","top_or_hot":-1,"title":"Citius Oncology Retains Jeffries to Consider Strategic Alternatives","media":"MT Newswires Live","content":"<html><body><p> Citius Pharmaceuticals' (CTXR) majority-owned subsidiary Citius Oncology (CTOR) said it has retained Jefferies as a financial advisor to evaluate possible strategic alternatives.</p><p>The company said alternatives being considered include partnerships, joint ventures, mergers, acquisitions, or licensing but has no specific timeline for a decision.</p><p>Citius Oncology Chief Executive Leonard Mazur said the \"goal is to deliver value to shareholders.\"</p><p>Citius Oncology's main product Lymphir was recently approved by the US Food and Drug Administration for the treatment of relapsed or refractory Stage I-III cutaneous T-cell lymphoma following at least one prior systemic therapy.</p><p>Citius Oncology shares were up more than 6% and Citius Pharmaceuticals more than 5% in Monday's premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Citius Oncology Retains Jeffries to Consider Strategic Alternatives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCitius Oncology Retains Jeffries to Consider Strategic Alternatives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-06 21:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Citius Pharmaceuticals' (CTXR) majority-owned subsidiary Citius Oncology (CTOR) said it has retained Jefferies as a financial advisor to evaluate possible strategic alternatives.The company said ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTXR","symbol_name":"Citius Pharmaceuticals, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2501234862","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501234862","pubTimestamp":1736170468,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Citius Pharmaceuticals'  majority-owned subsidiary Citius Oncology  said it has retained Jefferies as a financial advisor to evaluate possible strategic alternatives.The company said alternatives being considered include partnerships, joint ventures, mergers, acquisitions, or licensing but has no specific timeline for a decision.Citius Oncology Chief Executive Leonard Mazur said the \"goal is to deliver value to shareholders.\"Citius Oncology's main product Lymphir was recently approved by the US Food and Drug Administration for the treatment of relapsed or refractory Stage I-III cutaneous T-cell lymphoma following at least one prior systemic therapy.Citius Oncology shares were up more than 6% and Citius Pharmaceuticals more than 5% in Monday's premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CTXR":"Citius Pharmaceuticals, Inc.","BK4007":"制药","CTOR":"CITIUS ONCOLOGY INC","BK4139":"生物科技"},"translate_title":"Citius Oncology聘请Jeffries考虑战略替代方案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTOR":0.9,"CTXR":0.9},"content_text":"Citius Pharmaceuticals' (CTXR) majority-owned subsidiary Citius Oncology (CTOR) said it has retained Jefferies as a financial advisor to evaluate possible strategic alternatives.The company said alternatives being considered include partnerships, joint ventures, mergers, acquisitions, or licensing but has no specific timeline for a decision.Citius Oncology Chief Executive Leonard Mazur said the \"goal is to deliver value to shareholders.\"Citius Oncology's main product Lymphir was recently approved by the US Food and Drug Administration for the treatment of relapsed or refractory Stage I-III cutaneous T-cell lymphoma following at least one prior systemic therapy.Citius Oncology shares were up more than 6% and Citius Pharmaceuticals more than 5% in Monday's premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2501234862"}